Skip to main content
Clinicalinfo.HIV.gov logo.
In affiliation with HIV.gov
Main navigation
  • Home
  • About
  • Guidelines
  • Drug Database
  • Glossary
  • News
  • Resources
  • Contact Us
  • English
  • Español (Spanish)

Language:

  • English
  • Español

clinicalinfo.hiv.gov

Offering Information on HIV/AIDS Treatment, Prevention, and Research

Clinical Guidelines

Federally approved medical practice guidelines for HIV/AIDS.
Guidelines 

Drug Database

Information on FDA-approved HIV/AIDS and opportunistic infection drugs and investigational HIV/AIDS drugs. Drugs 

Glossary

Medical dictionary of HIV-related terms.
Glossary 

Resources

HIV-related resources from the National Institutes of Health.
Resources 

Overview

  • Read more about Overview

Table 5. Serious and/or Common Adverse Reactions Associated with Systemically Administered Drugs Used to Treat or Prevent Opportunistic Infections

  • Read more about Table 5. Serious and/or Common Adverse Reactions Associated with Systemically Administered Drugs Used to Treat or Prevent Opportunistic Infections

Table 4. Significant Pharmacokinetic Interactions Between Drugs Used to Treat or Prevent Opportunistic Infections

  • Read more about Table 4. Significant Pharmacokinetic Interactions Between Drugs Used to Treat or Prevent Opportunistic Infections

Table 3. Indications for Discontinuing and Restarting Primary and Secondary Prophylaxis (or Chronic Maintenance Therapy) for Selected Opportunistic Infections in Adults and Adolescents with HIV

  • Read more about Table 3. Indications for Discontinuing and Restarting Primary and Secondary Prophylaxis (or Chronic Maintenance Therapy) for Selected Opportunistic Infections in Adults and Adolescents with HIV

Table 2. Treatment of HIV-Associated Opportunistic Infections (Includes Recommendations for Acute Treatment and Secondary Prophylaxis/Chronic Suppressive/Maintenance Therapy)

  • Read more about Table 2. Treatment of HIV-Associated Opportunistic Infections (Includes Recommendations for Acute Treatment and Secondary Prophylaxis/Chronic Suppressive/Maintenance Therapy)

Table 1. Chemoprophylaxis to Prevent First Episode of Opportunistic Disease

  • Read more about Table 1. Chemoprophylaxis to Prevent First Episode of Opportunistic Disease

Appendix C: General Terms

  • Read more about Appendix C: General Terms

Appendix C: Drug Name Abbreviations

  • Read more about Appendix C: Drug Name Abbreviations

Drug-Drug Interactions: Integrase Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors or Protease Inhibitors

  • Read more about Drug-Drug Interactions: Integrase Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors or Protease Inhibitors

Drug-Drug Interactions: Non-Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors

  • Read more about Drug-Drug Interactions: Non-Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Current page 11
  • Page 12
  • Page 13
  • Page 14
  • Next page Next ›
  • Last page Last »

CONNECT WITH US

Footer menu

  • Home
  • About
  • Guidelines
  • Drug Database
  • Glossary
  • News
  • Resources
  • Contact Us
  • Sponsors
  • Nondiscrimination Notice
  • Accessibility
  • Disclaimers
  • Sitemap
  • Privacy Policy
  • HHS Vulnerability Disclosure

External links

  • HIVinfo.NIH.gov
  • HHS.gov
  • NIH.gov
  • Players & Viewers
  • HHS 508
  • HHS Privacy Policy
  • Whitehouse.gov
  • USA.gov
  • Freedom of Information Act

Provided in collaboration with NIH’s Office of AIDS Research.